Oric Pharmaceuticals (ORIC) Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025 summary

Key data and industry context

• Pfizer's MEVPRO data showed a strong rPFS benefit (hazard ratio 0.51), outperforming expectations and providing a robust proof of concept for PRC2 inhibitors in prostate cancer.

• Control arm performance in the MEVPRO study was consistent with historical benchmarks, validating the treatment effect observed.

• Safety profile for PRC2 inhibitors includes expected hematologic and GI toxicities, with potential for differentiation based on pharmacokinetics and dosing.

• Market opportunity for PRC2 inhibitors in prostate cancer is estimated at $5–10 billion, with precedent for multiple successful entrants in the AR inhibitor space.

• Pfizer's phase 3 trials are sized at 1,500 patients and $200 million, a scale considered feasible for smaller biotechs as well.

Program updates and forward-looking plans

• Plans to select recommended phase 2 doses for ORIC-944 combinations in Q2, with dose optimization and further data updates expected by Q4 or early next year.

• Phase 3 studies for ORIC-944 in CRPC are targeted to start in the first half of next year, aiming to close the timeline gap with Pfizer.

• NDA submissions for ORIC-944 are anticipated in the second half of 2027, following a similar timeline to Pfizer's MEVPRO program.

• Financial runway extends to late 2026, supporting multiple registrational studies and key data catalysts.

• No plans to independently pursue castration-sensitive prostate cancer studies; partnership sought for broader indications.

Competitive landscape and differentiation

• ORIC-944 and Pfizer's MEVPRO are more potent and have better pharmacokinetics than tazemetostat, which suffered from poor drug properties and trial design.

• Lower PSA50 rates in PRC2 inhibitor studies are explained by the mechanism's effect on PSA expression, but mature rPFS remains the key regulatory endpoint.

• Early ORIC-944 combo data show promising PSA responses, with durability and confirmation as important metrics.

• Differentiation from competitors is expected through improved safety, dosing convenience, and potential efficacy advantages.